

MBBS 2nd Prof Batch 2019
Teaching Schedule for Year 2021 Integration Module

Jaundice

Integration Module for Phase 2 Students (2021-2022) Total: 24.5 hrs

S. No	TLM	Lead	Competencies	Integration Method
1	1hr Lecture	Microbiology	Recap of Phase I	--
2	2 hr Lecture	Pathology	PA 25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences IM 5.12 Appropriate diagnostic tests for hepatitis	Nesting
3	2 hrs SGD	Microbiology	MI 3.7 Viral hepatitis – etiopathogenesis, viral markers, diagnosis, prevention CM 3.3 Aetiology & basis of water borne diseases/jaundice/ hepatitis	Sharing
4	1hr Lecture	Pathology	PA 25.4 Liver disease, Cirrhosis IM 5.6 Cirrhosis	Nesting
5	2 hr (SGD)	Medicine	IM5.3 Describe & discuss the pathology of various Liver diseases PA 25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences	Nesting
6	1 hr SGD	Microbiology	MI 3.7 etiopathogenesis, viral markers, diagnosis, prevention CM 3.3 Aetiology & basis of water borne diseases/jaundice/ hepatitis	Sharing
7	1:30 hr SGD	Forensic	FM9.4 Treatment of poisoning: decontamination, with regard to Ethanol, methanol, ethylene glycol PA 25.4 Alcoholic liver disease	Sharing
8	1hr Lecture	Pharma	PH1.48 Drugs used in Viral Disease IM 5.4 Describe & discuss infective hepatitis	Nesting
9	1hr Lecture	Pathology	PA 25.4 Alcoholic liver disease IM 5.5 Describe & discuss Alcoholic liver disease	Nesting
10	1 hr Lecture	Microbiology	MI 3.1,3.2 Parasitic infections causing Jaundice Fasciola hepatica PA 10.4 Define pathogenesis & pathology of viral diseases	Nesting
11	1hr Lecture	Community Medicine	CM 8.1 Describe & discuss epidemiological for communicable diseases IM: 5.4 Describe & discuss epidemiology of infective viral hepatitis	Nesting
12	1hr Lecture	Pathology	PA 25.3 Describe the etiology and pathogenesis of viral and toxic hepatitis FM9.2 Treatment of poisoning Phosphorus (Hepatotoxic)	Sharing
13	1 hr Lecture	Forensic	FM9.2 Treatment of poisoning Phosphorus (Hepatotoxic) PA 25.3 Describe the etiology and pathogenesis of toxic hepatitis	Sharing
14	2 hr Lecture	Microbiology	MI3.8 - Lab diagnosis of Viral hepatitis and other causes of hepatitis IM 5.12 Appropriate diagnostic tests for hepatitis	Nesting
15	1hr	Pharmacolog	PH1.48 Indication & CI of drugs used in Viral Disease	Nesting

	Lecture	y	IM 5.17 vaccination for hepatitis	
16	1hr Lecture	Pathology	PA 25.5 Portal Hypertension IM 5.6 Portal hypertension	Nesting
17	1hr Lecture	Forensic	FM9.3 Treatment mercury, copper poisoning IM: 5.7 Drug induced liver diseases	Nesting
18	1 hr Lecture	Community	CM5.7 food Hygiene Integrated IM: 5.7 Drug induced liver diseases	Nesting
19	1 hr Lecture	Pathology	Feedback	
20	1 hr Lecture	Pathology	Assessment	

Ischaemic Heart Disease
Integration Module for Phase 2 Students (2021-2022) **Total: 26 hrs**

S.No.	TLM	Lead Department	Competency	Integration
1	1Hr L	Pathology	Recap of Phase 1	--
2	2 Hr L	Pathology	PA 27.3 Heart Failure IM: 2.1 Discuss and describe the epidemiology and risk factors for atherosclerosis and IHD	Sharing
3	2 Hr L	Pharmacology	PY 2.8 Describe the physiological basis of hemostasis and, anticoagulants. Describe bleeding & clotting disorders IM2.3 Discuss and describe the lipid cycle and the role of dyslipidemia in the pathogenesis of atherosclerosis	Nesting
4	2 hr L	Pathology	PA 27.8 Cardiac functions in acute coronary syndrome BI 11.17 Explain the basis and rationale of biochemical tests done in myocardial infarction IM 2.4 Discuss and describe the pathogenesis, natural history, evolution and complications of atherosclerosis and IHD	Nesting
5	2 hr L	Pharmacology	PY 2.8 Describe the physiological basis of hemostasis and, anticoagulants. IM: 2.14 Discuss and describe indications for admission to a coronary care unit and supportive therapy for a patient with acute coronary syndrome	Nesting
6	2 hr SGD	Pharmacology	PH 1.28 Mechanism of action of drugs used in IHD IM 2.15 Discuss and describe the medications used in patients with an acute coronary syndrome PY 5.6 Describe the physiological basis of hemostasis and, anticoagulants.	Nesting
7	2 hr SGD	Pharmacology	PH 1.28 indications of drugs used in IHD IM: 2.23 Describe and discuss the indications for nitrates, anti-platelet agents, beta blockers, ACE inhibitors etc in the management of coronary syndromes, 2.15,. Discuss and describe the medications used in patients with an acute coronary syndrome	Nesting

8	2 hr SGD	Pharmacology	PH 1.28 Side effects and contraindications of drugs used in IHD IM 2.16 Discuss and describe the indications for acute thrombolysis	Nesting
9	1Hr L	Pharmacology	PH 1.28 side effects and contraindications of drugs used in IHD IM:2.15,. Discuss and describe the medications used in patients with an acute coronary syndrome based on the clinical presentation	Nesting
10	1Hr L	Pharmacology	PH 1.28 doses of drugs used in IHD IM: 2.23 indications for nitrates, anti platelet agents, gpIIb IIIa inhibitors, beta blockers, ACE inhibitors etc in the management of coronary syndromes,	Nesting
11	1Hr L	Pharmacology	PH1.25 anticoagulants IM: 2.23 indications for nitrates, anti platelet agents, gpIIb IIIa inhibitors, beta blockers, ACE inhibitors etc in the management of coronary syndromes,	Nesting
12	1Hr SGD	Pharmacology	PH1.25 antiplatelets PY 2.7, Describe the formation of platelets, functions and variations. IM 2.23 indications for anti platelet agents in the management of coronary syndromes,	Nesting
13	1Hr SGD	Pharmacology	PH1.29 Drugs used in congestive heart failure PH1.25 fibrinolytics PY 2.8, Describe the formation of platelets, functions and variation anti platelet agents, Describe bleeding & clotting disorders	Nesting
14	2hr SGD	Pharmacology	Ischemic Heart Disease (Case Based Discussion) PH 1.28 drugs used in IHD IM 2.23 indications for drugs in the management of coronary syndromes, IM: 2.24 Counsel and communicate to patients with empathy lifestyle changes in atherosclerosis / post coronary syndromes CM: 8.2 Describe and discuss the epidemiological and control measures including the use of essential laboratory tests at the primary care level for Non Communicable diseases	Nesting
15	1hr SGD	Medicine	Medicine IM: 2.23 indications for drugs in the management of coronary syndromes,,2.24 Counsel and communicate to patients with empathy lifestyle changes in atherosclerosis / post coronary syndromes PH 1.28 drugs used in IHD ,PA: 27.5 Ischaemic heart disease, CM: 8.2	Nesting
16	1Hr SGD	Pathology	PA 27.5 : complications of Ischaemic heart disease BI 4.4 Describe the structure and functions of lipoproteins, relations with atherosclerosis	Sharing
17	1 Hr L	Pathology	Feedback	
18	1Hr L	Pharmacology	Assessment	

Goitre
Integration Module for Phase II Students (2021) Total: 13 hrs

S.NO.	TLM	LEAD DEPARTMENT	COMPETENCY	INTEGRATION
1	1 hr SGD	Pharmacology	RECAP OF PHASE 1	
2	2 hr L	Pharmacology	PH1.36 Describe the mechanism of action, types , doses, side effects, indications and contraindications of drugs used in Thyroid disorders IM12.13 Describe the pharmacology, indications, adverse reaction, interactions of thyroxine and antithyroid drugs IM12.15 Describe and discuss the indications of thioamide therapy, radio iodine therapy and surgery in the management of thyrotoxicosis IM12.4 Describe and discuss the principles of radio iodine uptake	Nesting
3	2 hr SGD	Pharmacology	PH 1.55 Describe & discuss the following National Health Programmes..... And Iodine deficiency IM12.12 Describe and discuss the iodisation programs CM 8.3 Enumerate and describe disease specific National Health Programs including their prevention and treatment of a case	Sharing
4	1 hr SGD	Pathology	PA32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism IM12.2 Describe and discuss the genetic basis of some forms of thyroid dysfunction	Nesting
5	2 hr SGD	Pharmacology	PH1.10: Describe parts of a correct, complete and legible generic prescription. (Thyroid). Identify errors in prescription and correct appropriately IM12.14 Write and communicate to the patient appropriately a prescription for thyroxine based on age, sex and clinical and biochemical status	Nesting
6	3 hr DOAP	Medicine	IM12.5 Elicit document and present an appropriate history IM12.7 Demonstrate the correct technique to palpate the thyroid SU22.3 Demonstrate & document the correct clinical examination of thyroid swellings and discuss the differential diagnosis and their management SU 22.4 Describe the clinical features, classification and principles of management of thyroid cancer. IM12.9 Order and interpret diagnostic testing based on clinical diagnosis	Sharing
7	1 hr	Pathology	FEEDBACK	
8	1 hr	Pharmacology	ASSESSMENT	

Diabetes Mellitus
Integration Module for Phase II Students (2021) Total 18 hrs

S.No	TLM	Lead	Topic	Integration Method
1.	1hr L	Pharmacology	Recap of Diabetes Mellitus Phase I	Nesting
2.	2hr L	Community Medicine	CM8.2.4 Discuss the epidemiology of Diabetes IM 11.4 Describe & discuss the genetic background & the influence of the environment on diabetes	Sharing
3	2 hrs SGD	Pharmacology	PH1.36 Describe the mechanism of action, types doses, side effects, indications & contraindications of Sulphonylureas & Biguanides used in diabetes IM: 11.16 Discuss & describe the pharmacological therapies (Sulphonylureas & Biguanides) for diabetes, their indications, contraindications, adverse reactions & interactions	Nesting
4.	2hrs SGD	Pharmacology	PH1.36 Describe the mechanism of action, types doses, side effects, indications & contraindications of Thiazolidinediones & DPP4 inhibitors used in diabetes IM: 11.16 Discuss & describe the pharmacological therapies (Thiazolidinediones & DPP4) for diabetes, their indications, contraindications, adverse reactions & interactions	Nesting
5.	2hrs SGD	Pharmacology	PH1.36 Describe the mechanism of action, types doses, side effects, indications & contraindications of Alpha glucosidase inhibitors & SGLT-2 inhibitors used in diabetes IM: 11.18 Describe & discuss the pharmacology, indications, adverse reactions & interactions of drugs used in the prevention & treatment of target organ damage & complications of Type II diabetes	Nesting
6.	3hrs SGD	Medicine	CM 8.2.3 Discuss the control measures at PHC level for diabetes IM 11.17 Outline a therapeutic approach to therapy of T2Diabetes based on presentation, severity and complications in a cost effective manner PH1.36 Describe the indications & contraindications of drugs used in diabetes	Nesting
7.	3hrs SGD	Medicine	IM 11.17 Outline a therapeutic approach to therapy of T2Diabetes based on presentation, severity and complications in a cost effective manner PH1.36 Describe the indications & contraindications of drugs used in diabetes	Correlation
8.	1hr SGD	Pharmacology	PH 2.1 Understanding of the use of various dosage forms in Diabetes IM: 11.19 Demonstrate and counsel patients on the correct technique to administer insulin	Sharing
9.	1hr	Pharmacology	Feedback	
10.	1hr	Microbiology	Assessment	

GOVERNMENT MEDICAL COLLEGE AND RAJINDRA HOSPITAL, PATIALA

AIT – ANEMIA

MBBS PHASE 2

Total Hours - 20

S.No	TIME	LEAD	COMPETENCY	INTEGRATION
1	1 HOUR LECTURE	PHARMACOLOG Y	Recap of Phase 1	
2	3 HOUR LECTURE	PHARMACOLOG Y	PH 1.35 Indications and Contraindications of drugs used in Anemia IM 9.14 Prescribe replacement therapy with iron, b12, folate PE13.5 Propose a management plan for iron deficiency anemia PE13.6 Discuss the national anemia control programmes and its recommendations	NESTING
3	3 HOUR LECTURE	PATHOLOGY	PA 13.1 Describe hematopoiesis and extra medullary hematopoiesis PA13.3 Define and classify Anemia PA 13.4 Enumerate ad describe the investigations of anaemia IM 9.9 Describe and discuss the various tests of iron deficiency anemia	SHARING
4	3HOUR DOAP	PATHOLOGY	PA 13.5 Perform, identify and describe the peripheral blood picture in anemia. IM 9.10 Order and interpret tests for anemia including haemogram, red cell indices, reticulocyte count, iron studies, B12 and folate. IM 9.13 Describe, develop a diagnostic plan to determine the etiology of anemia.	Nesting
5	3 HOURS LECTURES	PATHOLOGY	PA16.1 Define and classify hemolytic anaemia. PA16.2 Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia PA 16.3 Describe the pathogenesis, features, hematologic indices and peripheral blood picture of sickle cell anemia. PA16.4 Describe the etiology, pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia PA16.5 Describe the peripheral blood picture in different hemolytic anemia. PE 29.4 Discuss the etio-pathogenesis clinical features and management of hemolytic Anemia, Thalassemia Major Sickle cell Anemia, Hereditary Spherocytosis, Autoimmune hemolytic anemia and hemolytic uremic syndrome.	Nesting
6	2HOUR DOAP	PATHOLOGY	PA 16.6 Prepare a peripheral blood smear and identify hemolytic anemia from it PA 16.7 Describe the correct technique to perform a cross match PE 29.1 Discuss etio-pathogenesis, clinical features, classification and approach to a child with anemia.	Nesting
7	2 HOUR SGD	PATHOLOGY	PA 17.1 Enumerate the etiology, pathogenesis and findings in aplastic anemia PA 17.2 Enumerate the indications and describe the findings in bone marrow aspiration and biopsy. PH 1.35 Indications and Contraindications of drugs used in Aplastic Anemia	Nesting
8	2HOUR	MICROBIOLOGY	MI 2.4 List the common microbial agents causing anemia. Describe the morphology, mode of infection and discuss the pathogenesis, clinical course, diagnosis, prevention,. And treatment of common microbial agents causing Anemia. IM9.15 Describe the national programmes for anaemia prevention	Nesting

9	1 HOUR	PATHOLOGY	Assessment / Feedback	
---	--------	-----------	-----------------------	--